Compare Adaptive Biotechnologies Corp (ADPT) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Banco Bilbao Vizcaya Argentaria SA trades at $25.25 (market cap $143.90B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 43.2× Adaptive Biotechnologies Corp's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.13% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | BBVA | |
|---|---|---|
Market Cap | $3.33B | $143.90B |
Sector | Health | Financials |
52-Week High | $22.37 | $26.14 |
52-Week Low | $10.24 | $14.73 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BBVA trades at $26.07, up 1.84% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.51% net income margin and 18.67% ROE, while recent Q1 2026 earnings beat expectations. Positive sentiment is driven by analyst upgrades and news highlighting European bank outperformance and strategic partnerships, though regulatory scrutiny in Spain presents a headwind.
The outlook remains favorable given solid earnings growth, high ROE, and a majority analyst buy rating. Key risks include antitrust investigations and volatile cash flows, but the stock's reasonable P/E of 12.61 and dividend yield offer value. Upside is contingent on sustained loan growth and execution in key markets like Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
